Clinical characteristics and analysis of prognostic factors in methicillin-resistant Staphylococcus aureus endocarditis: A retrospective multicenter study in Japan

J Infect Chemother. 2024 Dec;30(12):1259-1265. doi: 10.1016/j.jiac.2024.06.002. Epub 2024 Jun 12.

Abstract

Background: Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis.

Methods: This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019.

Results: A total of 65 patients from 19 centers were included, with a mean age of 67 years and 26 % were female. Fifty percent of the patients with IE were had nosocomial infections and 25 % had prosthetic valve involvement. The most common comorbidities were hemodialysis (20 %) and diabetes (20 %). Congestive heart failure was present in 86 % of patients (NYHA class I, II: 48 %; III, IV: 38 %). The 30-day and in-hospital mortality rates were 29 % and 46 %, respectively. Multi-organ failure was the primary cause of death, accounting for 43 % of all causes of death. Prognostic factors for in-hospital mortality were age, disseminated intravascular coagulation, daptomycin and/or linezolid as initial antibiotic therapy, and surgery. Surgical treatment was associated with a lower mortality rate (odds ratio [OR], 0.026; 95 % confidence interval [CI], 0.002-0.382; p = 0.008 for 30-day mortality and OR, 0.130; 95 % CI; 0.029-0.584; p = 0.008 for in-hospital mortality).

Conclusion: Mortality due to MRSA-IE remains high. Surgical treatment is a significant prognostic predictor of MRSA-IE.

Keywords: Endocarditis; Methicillin-resistant Staphylococcus aureus; Multi-organ failure; Prognosis; Surgical treatment.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents* / therapeutic use
  • Cross Infection* / drug therapy
  • Cross Infection* / epidemiology
  • Cross Infection* / microbiology
  • Cross Infection* / mortality
  • Endocarditis, Bacterial* / diagnosis
  • Endocarditis, Bacterial* / drug therapy
  • Endocarditis, Bacterial* / epidemiology
  • Endocarditis, Bacterial* / microbiology
  • Endocarditis, Bacterial* / mortality
  • Female
  • Hospital Mortality*
  • Humans
  • Japan / epidemiology
  • Male
  • Methicillin-Resistant Staphylococcus aureus* / isolation & purification
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Staphylococcal Infections* / diagnosis
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / epidemiology
  • Staphylococcal Infections* / microbiology
  • Staphylococcal Infections* / mortality

Substances

  • Anti-Bacterial Agents